Bio Path Holdings Stock Analysis
| BPTH Stock | USD 0.07 0.01 15.83% |
Bio Path Holdings holds a debt-to-equity ratio of 0.013. With a high degree of financial leverage come high-interest payments, which usually reduce Bio Path's Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
Bio Path's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Bio Path's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the OTC Stock is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Bio OTC Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Bio Path's stakeholders.
For many companies, including Bio Path, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Bio Path Holdings, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Bio Path's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Bio Path's debt-to-equity ratio measures a OTC Stock's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Bio Path is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Bio Path to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Bio Path is said to be less leveraged. If creditors hold a majority of Bio Path's assets, the OTC Stock is said to be highly leveraged.
Bio Path Holdings is overvalued with Real Value of 0.0569 and Hype Value of 0.06. The main objective of Bio Path otc analysis is to determine its intrinsic value, which is an estimate of what Bio Path Holdings is worth, separate from its market price. There are two main types of Bio Path's stock analysis: fundamental analysis and technical analysis.
The Bio Path otc stock is traded in the USA on OTCQX Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Bio Path's ongoing operational relationships across important fundamental and technical indicators.
Bio |
Bio OTC Stock Analysis Notes
The company recorded a loss per share of 8.34. Bio Path Holdings last dividend was issued on the 18th of January 2019. The entity had 1:20 split on the 23rd of February 2024. Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas. Bio-Path Holdings operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people.The quote for Bio Path Holdings is listed on Over The Counter exchange (i.e., OTC), and the entity is not required to meet listing requirements such as those found on the Nasdaq, NYSE, or AMEX exchanges. For more info on Bio Path Holdings please contact the company at 832 742 1357 or go to https://www.biopathholdings.com.Bio Path Holdings Investment Alerts
| Bio Path Holdings generated a negative expected return over the last 90 days | |
| Bio Path Holdings has high historical volatility and very poor performance | |
| Bio Path Holdings has some characteristics of a very speculative penny stock | |
| Bio Path Holdings has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (16.08 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Bio Path Holdings currently holds about 17.02 M in cash with (11.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.38, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Bio Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.21 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Bio Path's market, we take the total number of its shares issued and multiply it by Bio Path's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Technical Drivers
As of the 13th of February 2026, Bio Path shows the Mean Deviation of 6.28, risk adjusted performance of 0.0044, and Standard Deviation of 10.35. Bio Path Holdings technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate and analyze data for thirteen technical drivers for Bio Path Holdings, which can be compared to its peers.Bio Path Holdings Price Movement Analysis
Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Weighted Moving Average calculates a weight for each value in Bio Path price series with the more recent values given greater weights.
Bio Path Holdings Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bio Path insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bio Path's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bio Path insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bio Path Outstanding Bonds
Bio Path issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Bio Path Holdings uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Bio bonds can be classified according to their maturity, which is the date when Bio Path Holdings has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| BIO 33 15 MAR 27 Corp BondUS090572AR99 | View | |
| BIO 37 15 MAR 32 Corp BondUS090572AQ17 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View |
Bio Path Predictive Daily Indicators
Bio Path intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Bio Path otc stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 2251.52 | |||
| Daily Balance Of Power | 0.8261 | |||
| Rate Of Daily Change | 1.16 | |||
| Day Median Price | 0.0638 | |||
| Day Typical Price | 0.0657 | |||
| Price Action Indicator | 0.0105 | |||
| Period Momentum Indicator | 0.0095 |
Bio Path Forecast Models
Bio Path's time-series forecasting models are one of many Bio Path's otc stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Bio Path's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Bio Path Holdings Debt to Cash Allocation
Bio Path Holdings currently holds 113 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Bio Path Holdings has a current ratio of 15.26, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Bio Path until it has trouble settling it off, either with new capital or with free cash flow. So, Bio Path's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Bio Path Holdings sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Bio to invest in growth at high rates of return. When we think about Bio Path's use of debt, we should always consider it together with cash and equity.Bio Path Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Bio Path's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Bio Path, which in turn will lower the firm's financial flexibility.Bio Path Corporate Bonds Issued
Most Bio bonds can be classified according to their maturity, which is the date when Bio Path Holdings has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
About Bio OTC Stock Analysis
OTC Stock analysis is the technique used by a trader or investor to examine and evaluate how Bio Path prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Bio shares will generate the highest return on investment. We also built our otc analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual OTC such as Bio Path. By using and applying Bio OTC Stock analysis, traders can create a robust methodology for identifying Bio entry and exit points for their positions.
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas. Bio-Path Holdings operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our otc stock analysis tools, you can find out how much better you can do when adding Bio Path to your portfolios without increasing risk or reducing expected return.Did you try this?
Run USA ETFs Now
USA ETFsFind actively traded Exchange Traded Funds (ETF) in USA |
| All Next | Launch Module |
Complementary Tools for Bio OTC Stock analysis
When running Bio Path's price analysis, check to measure Bio Path's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Path is operating at the current time. Most of Bio Path's value examination focuses on studying past and present price action to predict the probability of Bio Path's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Path's price. Additionally, you may evaluate how the addition of Bio Path to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |